Favorable safety profile and encouraging early efficacy signals support advancement to Phase II trial of dendritic cell vaccine for the treatment of glioblastoma. "This milestone represents a ...
Researchers with Diakonos Oncology are working to extend the lives of other patients diagnosed with other forms of cancer.
HOUSTON, March 18, 2026 /PRNewswire/ -- Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, ...
HOUSTON--(BUSINESS WIRE)--Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
HOUSTON--(BUSINESS WIRE)--Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that it will present at the Emerging Growth Conference on Wednesday, ...
HOUSTON, May 29, 2025 /PRNewswire/ -- Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today ...
The MarketWatch News Department was not involved in the creation of this content. -- At $11.4M, the oversubscribed financing is expected to fund operations into late 2025. -- Topline safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results